Table 3

Infection Complications: Food and Drug Administration Investigational Device Exemption Study of the Charité Artificial Disc

Investigational Group (N = 205)Control Group (N = 99)P
All infection complications, no. (%)26 (12.7)8 (8.1).233
Superficial wound with incision site pain, no. (%)13 (6.3)2 (2.0).103
Other non-wound related, no. (%)5 (2.4)1 (1.0)
Urinary tract infection, no. (%)5 (2.4)1 (1.0)
Wound swelling, no. (%)2 (1.0)0
Pulmonary complication, no. (%)1 (0.5)0
Peritonitis, no. (%)01 (1.0)
Iliac crest donor site, no. (%)03 (3.0)
  • Note. Fisher's exact test was used to test categorical variables